Meet the speakers of CityU – AFCR Symposium – Min Li

CityU-AFCR Symposium on Precision Medicine and Digital Medicine will go on from 12-13 September as part of BIOHK2024.

The symposium will showcase presentations by BRACE award winners and experts in precision medicine, providing a dynamic platform for the exchange of innovative ideas and fostering a collaborative environment for advancements in the biotechnology field.

One of the Speakers is Min Li

Dr. Min Li is George Lynn Cross Research Professor of Medicine, Surgery, and Cell Biology at The University of Oklahoma Health Sciences Center (OUHSC), and holds the Virginia Kerley Cade Endowed Chair in Cancer Treatment. He is the Assistant Dean for International Research Collaboration at the College of Medicine, and Associate Director for Global Oncology at the NCI-designated Stephenson Cancer Center (SCC). He is also Director of GI Cancer Research at the Department of Medicine, and Vice Chair for Research at the Department of Surgery, and Co-Leader of Cancer Biology Program of SCC at OUHSC.

Dr. Li is a leading expert on pancreatic cancer (PC), and his research mainly focuses on studying PC pathogenesis and developing new therapies. Dr. Li’s group is the first to identify a key zinc transporter ZIP4, which is aberrantly expressed in PC, and promotes cancer growth, drug resistance, muscle wasting, cachexia, and metastasis. He has published more than 200 papers on high impact journals such as PNAS, EMBO Mol Med, Nature, Nature Communications, Gastroenterology, Can Res, Clin Can Res, JAMA Network Open, EBioMedicine (by Lancet), etc., and has four active NIH/NCI R01 grants, and multiple private foundation grants.

Dr. Li is a member of many NIH study sections, such as Developmental Therapeutics (DT), Cancer Etiology (CE), Basic Mechanism of Cancer Therapy (BMCT), Clinical Oncology (CONC), Mouse Model of Translational Cancer Research (MMTR), GI SPORE, Omnibus R21, DoD Cancer Research Program, AACR Pancreatic cancer action network (PanCAN), French NCI, Austrian Science Fund, Prostate Cancer UK, etc. He also serve as Editor-in-Chief, Deputy Editor, and editorial board member for many prestigious journals such as Cancer Letters, Clin Can Res, and BMC Medicine.

Dr. Li holds many important administrative positions in OUHSC, and he serve on multiple committees locally, nationally, and internationally. Dr. Li is the current President of American Pancreatic Association (APA). He is also the council member of the International Association for Pancreatology (IAP). He received many awards such as the Outstanding Achievement Award of IAP, and the Provost Research Award at OUHSC. He was nominated to National Academy of Medicine in 2022.

During CityU – AFCR Symposium Min Li  will speak about a topic named ‘Pancreatic Cancer Precision Medicine ‘ on September 12.

For more information about CityU-AFCR Symposium visit oncodaily.com